Literature DB >> 3098862

Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa.

J W Ogle, J M Janda, D E Woods, M L Vasil.   

Abstract

We used DNA restriction fragments, derived from the exotoxin A gene and surrounding sequences, as an epidemiological marker for Pseudomonas aeruginosa. Using these DNA fragments as probes in Southern blot hybridizations and/or total genomic digestions, we were able to distinguish greater than 100 different strains of P. aeruginosa. The stability of the marker in vitro was established by using well-characterized strains, which were stored under different conditions and subjected to chemical mutagenesis. The stability of the marker within a given strain in vivo was established during experimental infection in the chronic rat lung model of pseudomonas pneumonia. P. aeruginosa serially cultured from individual patients with cystic fibrosis were examined by using this marker. Isolates that varied in colonial morphology, serotype, and biotype were identical when analyzed by Southern blot hybridization using the fragment as a probe. Indistinguishable isolates (by serotyping, biotyping, and antibiograms) cultured from two unrelated patients were easily distinguished by using Southern blot analysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3098862     DOI: 10.1093/infdis/155.1.119

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  62 in total

1.  Evaluation of random amplified polymorphic DNA typing of Pseudomonas aeruginosa.

Authors:  M Campbell; E Mahenthiralingam; D P Speert
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

2.  Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.

Authors:  E Bingen; E Denamur; B Picard; P Goullet; N Lambert-Zechovsky; P Foucaud; J Navarro; J Elion
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

3.  Typing of coagulase-negative staphylococci by Southern hybridization of chromosomal DNA fingerprints using a ribosomal RNA probe.

Authors:  H Bialkowska-Hobrzanska; V Harry; D Jaskot; O Hammerberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

4.  The MerR-like transcriptional regulator BrlR contributes to Pseudomonas aeruginosa biofilm tolerance.

Authors:  Julie Liao; Karin Sauer
Journal:  J Bacteriol       Date:  2012-06-22       Impact factor: 3.490

5.  Genetic heterogeneity in strains of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  J W Ogle; M L Vasil
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

6.  Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis.

Authors:  T R Anderson; T C Montie; M D Murphy; V P McCarthy
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

7.  Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets.

Authors:  G Döring; H Bareth; A Gairing; C Wolz; K Botzenhart
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

8.  Risk of cross-colonization and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients.

Authors:  J A Hoogkamp-Korstanje; J F Meis; J Kissing; J van der Laag; W J Melchers
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa.

Authors:  H Grundmann; C Schneider; D Hartung; F D Daschner; T L Pitt
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Pseudomonas aeruginosa clinical isolates: serotypes, resistance phenotypes and plasmid profiles.

Authors:  M Millesimo; G de Intinis; M G Chirillo; T Musso; D Savoia
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.